Abstract:Serous endometrial and ovarian cancers represent significant morbidity and mortality for gynecologic cancers due to the high rate of resistance to chemotherapy and recurrence after treatment. Among the many reasons for poor outcomes is a lack of preclinical models that reflect the complex heterogeneity across patients. Our objective was to create patient-derived organoid (PDO) models of serous endometrial and ovarian cancer and examine how genomic profiles evolve in response to standard therapy. This study was performed in four PDO models of serous gynecologic cancer, including serous endometrial, high grade and low grade serous ovarian, and high grade serous fallopian tube. We first compared genomic alterations in the primary tumors and PDOs using a 484-gene NGS panel (NovoPM 2.0, Novogene). A large overlap in single nucleotide variants (SNVs), copy number variations (CNVs) and indels was observed between primary tumor tissue and the corresponding PDO model. For example, there was an average of 175 shared SNVs between each primary tumor and PDO model and <20 unique variants in the PDO that were not present in primary tumor specimen. For the patient with serous fallopian tube cancer, we were further able to generate PDO models from tumor tissue acquired from three different sites: ovary, omentum, and ascites fluid. We found that 217 SNVs were shared among the PDOs from the three sites, with only 2-11 variants unique to each location. Interestingly, eight unique CNVs were detected in the ovary and ascites PDOs but not in the metastatic (omentum) PDO. We next exposed each PDO to a short 3-day pulse of carboplatin+paclitaxel to create chemoexposed models. The rationale for this duration of exposure is that clinical response in patients has been shown to correlate with drug response at 72 hrs in PDO models of ovarian cancer. As expected, all chemoexposed PDOs were more resistant to chemotherapy as compared to treatment-naïve counterparts. Genomic analysis of the treatment-naïve vs. chemoexposed PDOs revealed acquisition of new variants, such as a p53 mutation in the serous endometrial model after the pulse of chemotherapy. Finally, we compared drug sensitivity of the treatment-naïve vs. chemoexposed PDOs to agents used in the adjuvant and recurrent settings. The chemoexposed models yielded different drug profiles, with some showing increased sensitivity and others increased resistance. Taken together, these data substantiate that PDO models retain tumor heterogeneity, exhibited by the different genomic profiles and varying chemosensitivity. In addition, PDO models can be used to model the genomic and drug response profiles that arise in response to chemotherapy. Citation Format: Andreea Newtson, Emily Symons, Paige Malmrose, Eric Devor, Samantha Parks, Craig Rush, Jessica Andrew-Udoh, Haley Losh, Jay Gertz, Kristina Thiel, Kimberly Leslie. Use of patient-derived organoids to model tumor evolution in response to chemotherapy [abstract]. In: Proceedings of the AACR Special Conference on Endometrial Cancer: Transforming Care through Science; 2023 Nov 16-18; Boston, Massachusetts. Philadelphia (PA): AACR; Clin Cancer Res 2024;30(5_Suppl) nr B032.

A novel patient derived orthotopic xenograft model of gastro-esophageal junction cancer: Key platform for translational discoveries.

A novel patient-derived orthotopic xenograft model of esophageal adenocarcinoma provides a platform for translational discoveries

Establishment of Patient-Derived Gastric Cancer Xenografts: a Useful Tool for Preclinical Evaluation of Targeted Therapies Involving Alterations in HER-2, MET and FGFR2 Signaling Pathways

Establishing A Patient-Derived Colorectal Cancer Xenograft Model For Translational Research

Establishment of a PDTT xenograft model of gastric carcinoma and its application in personalized therapeutic regimen selection.

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Patient-derived xenograft models for gastrointestinal tumors: A single-center retrospective study

Challenges and Prospects of Patient-Derived Xenografts for Cancer Research

An Orthotopic Patient-Derived Xenograft (PDX) Model Allows the Analysis of Metastasis-Associated Features in Colorectal Cancer

A novel patient-derived organoids-based xenografts model for preclinical drug response testing in patients with colorectal liver metastases

Promising preclinical patient-derived organoid (PDO) and xenograft (PDX) models in upper gastrointestinal cancers: progress and challenges

Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model

TMOD-08. PRIMARY AND RECURRENT GLIOMA PATIENT-DERIVED ORTHOTOPIC XENOGRAFTS (PDOX) REPRESENT RELEVANT PATIENT AVATARS FOR PRECISION MEDICINE

Establishment of a Patient-Derived Orthotopic Xenograft (PDOX) Model of HER-2-Positive Cervical Cancer Expressing the Clinical Metastatic Pattern

Gastric cancer patient-derived organoids model for the therapeutic drug screening

269. PATIENT-DERIVED TUMOR ORGANOIDS AND XENOGRAFTS AS BASIC AND PRECLINICAL TRANSLATIONAL ESOPHAGEAL SQUAMOUS CELL CARCINOMA MODELS

OS10.5.A Modeling immunocompetent tumor microenvironment in glioblastoma patient-derived orthotopic xenografts

Abstract 3855: Excavation of Therapeutic Targets Based on the Molecular Signature of Patient-Derived Tumor Xenografts in Gastric Cancer

Abstract B032: Use of patient-derived organoids to model tumor evolution in response to chemotherapy

Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing

Patient-derived Organoids (pdos) and PDO-derived Xenografts (pdoxs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models